Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/26
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 05/07/26
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026GlobeNewsWire • 05/05/26
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation PatientsGlobeNewsWire • 04/27/26
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 03/05/26
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026GlobeNewsWire • 03/02/26
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?Zacks Investment Research • 02/23/26
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?Zacks Investment Research • 01/30/26
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026GlobeNewsWire • 01/29/26
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?Zacks Investment Research • 01/23/26
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?Zacks Investment Research • 01/20/26